Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NRNT-062501
- Development stage
- Preclinical
- Lead developer
- Neurentis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NRNT-062501 is a preclinical-stage small molecule therapeutic being developed by Neurentis for the treatment of Progressive Supranuclear Palsy (PSP). PSP is a rare and debilitating neurodegenerative disorder characterized by the pathological accumulation of tau protein aggregates in the brain, leading to progressive motor, cognitive, and behavioral decline. Neurentis is currently pursuing orphan drug designation for NRNT-062501 as part of its portfolio focused on neurodegenerative conditions. While the specific molecular target has not been publicly disclosed, the drug is part of a pipeline aimed at addressing the underlying mechanisms of proteinopathy in the central nervous system.
Beyond the preview
Go deeper on NRNT-062501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NRNT-062501.